Table 5. Association between patient characteristics and response to CPS.
| Variable | N | Response (%) | P* |
|---|---|---|---|
| Sex | |||
| Male | 101 | 74 | 0.103 |
| Female | 92 | 83 | |
| CKD stage | |||
| Stage 2 | 6 | 75 | 0.658 |
| Stage 3 | 86 | 82 | |
| Stage 4 | 70 | 76 | |
| Stage 5 | 31 | 74 | |
| CPS formula | |||
| Kalimate® | 139 | 81 | 0.123 |
| Argamate® | 54 | 72 | |
| ACEI/ARB | |||
| Use | 114 | 74 | 0.024 |
| No use | 79 | 86 |
CKD, chronic kidney disease; CPS, calcium polystyrene sulfonate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blockade.
*Chi-square tests were used to compare dichotomous variables.